|
|
|
|
| LEADER |
04075nma a2201141 u 4500 |
| 001 |
EB002043926 |
| 003 |
EBX01000000000000001187592 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036539294
|
| 020 |
|
|
|a books978-3-0365-3929-4
|
| 020 |
|
|
|a 9783036539300
|
| 100 |
1 |
|
|a Kodjikian, Laurent
|
| 245 |
0 |
0 |
|a Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (246 p.)
|
| 653 |
|
|
|a meteorin
|
| 653 |
|
|
|a effectiveness
|
| 653 |
|
|
|a long-term FU
|
| 653 |
|
|
|a identification
|
| 653 |
|
|
|a Sorsby's fundus dystrophy
|
| 653 |
|
|
|a retina
|
| 653 |
|
|
|a neovascular age-related macular degeneration (nAMD)
|
| 653 |
|
|
|a treatment change
|
| 653 |
|
|
|a angiogenesis
|
| 653 |
|
|
|a epithelial tear
|
| 653 |
|
|
|a exudation
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a cataract surgery
|
| 653 |
|
|
|a ranibizumab
|
| 653 |
|
|
|a STARS®
|
| 653 |
|
|
|a treat and extend
|
| 653 |
|
|
|a intravitreal anti-vascular endothelial growth factor
|
| 653 |
|
|
|a fellow eye
|
| 653 |
|
|
|a cardiovascular risk factors
|
| 653 |
|
|
|a Delphi
|
| 653 |
|
|
|a lifestyle
|
| 653 |
|
|
|a hereditary retinal dystrophy
|
| 653 |
|
|
|a macular neovascularization
|
| 653 |
|
|
|a ForeseeHome AMD Monitoring System®
|
| 653 |
|
|
|a aflibercept monotherapy
|
| 653 |
|
|
|a meta-analysis
|
| 653 |
|
|
|a clinical trials
|
| 653 |
|
|
|a Sorsby
|
| 653 |
|
|
|a bevacizumab
|
| 653 |
|
|
|a risk
|
| 653 |
|
|
|a meta-regression
|
| 653 |
|
|
|a treat-and-extend
|
| 653 |
|
|
|a reading acuity
|
| 653 |
|
|
|a food supplement
|
| 653 |
|
|
|a visual acuity
|
| 653 |
|
|
|a treatment-naive
|
| 653 |
|
|
|a aflibercept
|
| 653 |
|
|
|a polypoidal choroidal vasculopathy
|
| 653 |
|
|
|a Vascular Endothelial Growth Factor (VEGF)
|
| 653 |
|
|
|a choroidal neovascularization
|
| 653 |
|
|
|a age-related macular degeneration
|
| 653 |
|
|
|a superficial perifoveal capillary plexus
|
| 653 |
|
|
|a comparative therapies
|
| 653 |
|
|
|a therapeutic innovation
|
| 653 |
|
|
|a nutrients
|
| 653 |
|
|
|a macula-off rhegmatogenous detachment
|
| 653 |
|
|
|a choroidal neovascularisation
|
| 653 |
|
|
|a real-world evidence
|
| 653 |
|
|
|a neovascular age-related macular degeneration
|
| 653 |
|
|
|a good baseline visual acuity
|
| 653 |
|
|
|a emerging treatment
|
| 653 |
|
|
|a arterial hypertension
|
| 653 |
|
|
|a pro re nata regimen
|
| 653 |
|
|
|a disease activity
|
| 653 |
|
|
|a switch therapy
|
| 653 |
|
|
|a optical coherence tomography
|
| 653 |
|
|
|a prevention
|
| 653 |
|
|
|a optical coherence tomography angiography
|
| 653 |
|
|
|a retinal deep perifoveal capillary plexus
|
| 653 |
|
|
|a treatment outcome
|
| 653 |
|
|
|a AREDS2-HOME study
|
| 653 |
|
|
|a brolucizumab
|
| 653 |
|
|
|a choriocapillaris
|
| 653 |
|
|
|a age-related macular degeneration (AMD)
|
| 653 |
|
|
|a quiescent macular neovascularization
|
| 653 |
|
|
|a anti-VEGF treatment
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a anti-VEGF
|
| 653 |
|
|
|a AMD
|
| 653 |
|
|
|a anti-vascular endothelial growth factor
|
| 653 |
|
|
|a oct-angiography
|
| 700 |
1 |
|
|a Kodjikian, Laurent
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-3929-4
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/81005
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5347
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients' quality of life.
|